Karyopharm Therapeutics Inc. Stock
A very strong showing by Karyopharm Therapeutics Inc. today, with an increase of €0.045 (4.380%) compared to yesterday's price.
We see a rather positive sentiment for Karyopharm Therapeutics Inc. with 7 Buy predictions and 2 Sell predictions.
With a target price of 3 € there is potential for a 185.58% increase which would mean more than doubling the current price of 1.05 € for Karyopharm Therapeutics Inc..
Our community identified positive and negative aspects for Karyopharm Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Karyopharm Therapeutics Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.
Pros and Cons of Karyopharm Therapeutics Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Karyopharm Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. | 4.380% | 5.303% | -11.871% | -67.637% | 26.080% | -86.648% | - |
| Ardelyx Inc. | 28.120% | 34.723% | 18.969% | 89.624% | 39.758% | 44.250% | - |
| Evolus Inc | 10.280% | 12.381% | -5.600% | 60.544% | 30.387% | 60.544% | - |
| Salarius Pharmaceuticals Inc. | 11.650% | 7.981% | 17.949% | -67.606% | -17.117% | -98.248% | -99.993% |
Comments
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Royal Bank of Canada from $4.00 to $3.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Royal Bank of Canada from $5.00 to $4.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
News
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Karyopharm Therapeutics (NASDAQ: KPTI)Q4 2023 Earnings CallFeb 29, 2024, 8:00 a.m. ET
Operator
Source Fool.com
